A new partnership has just been signed between Baylor College of Medicine and Miraca Holdings, Inc. that grants the two parties joint-ownership and control over Baylor’s clinical genetics diagnostic laboratories. Out of this new partnership will come Baylor Miraca Genetics Laboratories, which is expected to strengthen research and development on clinical laboratory genetic testing. The contract will be subject to regulatory approvals and mandatory closing conditions. This new joint venture will be based in Houston, Texas, and will employ an initial team of 225 people.
Japan-based Miraca Holdings specializes in in-vitro diagnostics, clinical laboratory testing, and several other healthcare businesses. Its subdivisions, Fujirebio, Inc. — an in-vitro diagnostic reagent developer, and SRL, Inc., a clinical laboratory testing company — are some of the largest in Japan. The holding company also owns Miraca Life Sciences, the United State’s largest independent anatomic pathology business, located in Irving, Texas.
Miraca’s impressive portfolio of healthcare business support and expansion businesses is expected to significantly enhance Baylor’s 35-year experience in providing diagnostic services. At the moment, Baylor ranks first among the National Institutes of Health-funded genetics programs, and operates one of only three large-scale genome sequencing centers in the country. Under the joint venture’s agreement, all faculty members from BCM involved in the college’s clinical diagnostics will retain their professorial positions, and Baylor’s educational training programs in genetics and sequencing will remain part of the school, but will be enhanced by Miraca’s wider international scope.
“Academic medical centers and teaching hospitals in Houston have lagged behind other areas of the country in commercializing medical inventions developed in their laboratories,” said Dr. Paul Klotman, President, CEO, Executive Dean, Baylor College of Medicine. “With partnerships such as this, the potential for growing biotech into a major economic driver for Houston and the Texas Medical Center is tremendous.”
Both Dr. Klotman and the President and CEO of Miraca Holdings, Dr. Hiromasa Suzuki look forward to the fruition of this joint venture’s great potentials. Baylor’s genetics and genome sequencing expertise will be strengthened on an international level with Miraca’s business acumen and tested strategies, while Miraca builds its name as a top-tier provider of novel genetic business in America.